Journal of Cardiac Failure
Volume 14, Issue 4 , Pages 320-326 , May 2008

The Synergism Between Atrial Fibrillation and Heart Failure

  • Melissa Byrne, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Melissa Byrne, Baker Heart Research Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria 8008, Australia.
    • ,
  • David M. Kaye, MD, PhD
    • ,
  • John Power, PhD

Received 20 July 2007 ,Revised 9 November 2007 ,Accepted 19 December 2007.

References 

  1. Cleland JG, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev. 2002;7:229–242
  2. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84:40–48
  3. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI102–VI110
  4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293–302
  5. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol. 1998;32:197–204
  6. Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am Heart J. 2005;150:701–706
  7. Byrne MJ, Raman JS, Alferness CA, Esler MD, Kaye DM, Power JM. An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. J Card Fail. 2002;8:108–115
  8. Medvedev OS, Esler MD, Angus JA, Cox HS, Eisenhofer G. Simultaneous determination of plasma noradrenaline and adrenaline kinetics. Responses to nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia in the rabbit. Naunyn Schmiedebergs Arch Pharmacol. 1990;341:192–199
  9. Pemberton CJ, Yandle TG, Charles CJ, Rademaker MT, Aitken GD, Espiner EA. Ovine brain natriuretic peptide in cardiac tissues and plasma: effects of cardiac hypertrophy and heart failure on tissue concentration and molecular forms. J Endocrinol. 1997;155:541–550
  10. Byrne MJ KD, Mathis M, Reuter DG, Alferness CA, Power JM. Percutaneous mitral annular reduction provides continued benefit in an ovine model of dilated cardiomyopathy. Circulation. 2004;110:3088–3092
  11. Kaye DM BM, Alferness C, Power J. Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of heart failure-induced mitral regurgitation. Circulation. 2003;108:1795–1797
  12. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87–95
  13. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101:2631–2638
  14. Van den Berg MP, Tuinenburg AE, Crijns HJ, Van Gelder IC, Gosselink AT, Lie KI. Heart failure and atrial fibrillation: current concepts and controversies. Heart. 1997;77:309–313
  15. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30:1039–1045
  16. Crijns HJ, Van den Berg MP, Van Gelder IC, Van Veldhuisen DJ. Management of atrial fibrillation in the setting of heart failure. Eur Heart J. 1997;18(Suppl C):C45–C49
  17. Jais P, Peng JT, Shah DC, Garrigue S, Hocini M, Yamane T, et al. Left ventricular diastolic dysfunction in patients with so-called lone atrial fibrillation. J Cardiovasc Electrophysiol. 2000;11:623–625
  18. Lau CP, Leung WH, Wong CK, Cheng CH. Haemodynamics of induced atrial fibrillation: a comparative assessment with sinus rhythm, atrial and ventricular pacing. Eur Heart J. 1990;11:219–224
  19. Alboni P, Scarfo S, Fuca G, Paparella N, Yannacopulu P. Hemodynamics of idiopathic paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 1995;18:980–985
  20. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169–175
  21. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823
  22. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257–1263
  23. Jayachandran JV, Sih HJ, Winkle W, Zipes DP, Hutchins GD, Olgin JE. Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation. 2000;101:1185–1191
  24. Friedman HS, Rodney E, Sinha B, Sharafkhaneh A, Wattanasuwan N, Win M, et al. Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. J Investig Med. 1999;47:293–303
  25. Wasmund SL, Li JM, Page RL, Joglar JA, Kowal RC, Smith ML, et al. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation. 2003;107:2011–2015
  26. Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami G, Arai H, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res. 1991;69:491–500
  27. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J. 1999;20:1799–1807
  28. Ohta Y, Shimada T, Yoshitomi H, Inoue S, Murakami Y, Shimizu H, et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol. 2001;17:415–420
  29. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000;6:92–96
  30. Jourdain P, Bellorini M, Funck F, Fulla Y, Guillard N, Loiret J, et al. Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study. Eur J Heart Fail. 2002;4:263–267
  31. Rossi A, Enriquez-Sarano M, Burnett JC, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000;35:1256–1262
  32. Horie H, Tsutamoto T, Minai K, Hayashi M, Kito O, Kinoshita M. Brain natriuretic peptide predicts chronic atrial fibrillation after ventricular pacing in patients with sick sinus syndrome. Jpn Circ J. 2000;64:965–970
  33. Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J. 2000;64:765–771
  34. Doyama K, Fukumoto M, Takemura G, Tanaka M, Oda T, Hasegawa K, et al. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol. 1998;32:1832–1838
  35. Margulies KB, Hildebrand FL, Lerman A, Perrella MA, Burnett JC. Increased endothelin in experimental heart failure. Circulation. 1990;82:2226–2230
  36. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374–1379
  37. Love MP, McMurray JJ. Endothelin in congestive heart failure. Basic Res Cardiol. 1996;91:21–29
  38. Tuinenburg AE, Van Veldhuisen DJ, Boomsma F, Van Den Berg MP, De Kam PJ, Crijns HJ. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol. 1998;81:1207–1210
  39. Brundel BJ, Van Gelder IC, Tuinenburg AE, Wietses M, Van Veldhuisen DJ, Van Gilst WH, et al. Endothelin system in human persistent and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2001;12:737–742
  40. Verheule S, Wilson E, Everett TT, Shanbhag S, Golden C, Olgin J. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation. 2003;107:2615–2622
  41. Junker A, Thayssen P, Nielsen B, Andersen PE. The hemodynamic and prognostic significance of echo-Doppler-proven mitral regurgitation in patients with dilated cardiomyopathy. Cardiology. 1993;83:14–20

PII: S1071-9164(07)01164-5

doi: 10.1016/j.cardfail.2007.12.005

Journal of Cardiac Failure
Volume 14, Issue 4 , Pages 320-326 , May 2008

Article Tools

* Image Usage & Resolution